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Title: High-throughput drug screens for 
amyotrophic lateral sclerosis drug discovery 
Abstract: 
 Amyotrophic lateral sclerosis (ALS) is a rapid adult onset neurodegenerative disorder 
characterised by the progressive loss of upper and lower motor neurons. Current 
treatment options are limited for ALS, with very modest effects on survival. There is a need 
for novel therapeutics to treat ALS and in this review we discuss the high-throughput drug 
screening efforts to identify novel compounds. 
Areas covered: 
 This review highlights the many diverse high-throughput screening platforms that have 
been implemented in ALS drug discovery. The authors discuss cell free assays including in 
silico and protein interaction models. The review covers classical in vitro cell studies and 
new cell technologies, such as patient derived cell lines. Finally the review looks at novel in 
vivo models and their use in high-throughput ALS drug discovery 
Expert opinions: 
 In the expert opinions section, the authors summarize the successes of high-throughput 
screening in ALS as well as the areas where future work can be directed. We also highlight 
new and emerging technologies, such as artificial intelligence and biomarker 
identification, as being critical in finding new treatments for this devastating disease. 
 Key Words: Amyotrophic lateral sclerosis (ALS), drug discovery, high-throughput drug screening 
(HTDS). 
All figure and tables in this work are original and no permissions are required 
Article highlights  
x The current treatments for patients with ALS are modest in effect and there is a need for 
better treatments for this devastating disease  
x A large number of high-throughput drug screens have been performed to identify novel 
ALS therapeutics 
x Screens have been performed using a wide range of different model systems, various 
genetic subtypes of ALS, as well as aiming for a wide range of different molecular targets 
and/or phenotypic outcomes - highlighting the complexity of ALS and necessity for careful 
study design 
Greater use of patient-derived in vitro cell models and development of better animal models of 
ALS will improve translation of lead compounds into clinic 
 
 
 
 
 
 
1. Introduction  
Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disorder that is 
characterised by the loss of upper and lower motor neurons (MN) in the brain and spinal cord. 
Patients develop progressive muscle weakness and paralysis, with death typically 2-5 years from 
disease onset. 90% of ALS cases are sporadic in nature, while hundreds of variants in over 30 genes 
are known to cause familial ALS. The most common genetic cause of ALS is a GGGGCC 
hexanucleotide repeat expansion in the first intron of C9ORF72, accounting for 40% of familial and 
7% of sporadic ALS cases 1-3. Superoxide dismutase 1 (SOD1) encodes an enzyme that acts as a free 
radical scavenger in the cell, and in 1993, was the first gene in which mutations were identified to 
cause ALS. SOD1 mutations account for approximately 20-25% of familial cases 4, 5, and is the most 
investigated gene in the ALS field, mainly due to its early discover. Therefore, the majority of high 
throughput screens performed in the field have focused on mutant SOD1. TAR DNA-binding protein 
43 (TARDBP) encodes TDP-43, a ubiquitously expressed RNA/DNA binding protein which is heavily 
implicated in ALS pathogenesis. TDP-43-positive cytoplasmic inclusions appear in the majority of 
both sporadic and familial ALS cases, and TARDBP mutations also account for 1-3% of familial ALS 
cases 6, 7. Therefore, reducing TDP-43 proteinopathy has been a focus of high-throughput drug 
screens (HTDS). 
Treatment options for ALS are limited, with the majority of treatment options palliative in nature. 
Currently 2 drugs are licenced for the treatment of ALS: riluzole and edaravone. Riluzole was the first 
FDA approved treatment for ALS and acts by blocking TTX sensitive sodium channels, inhibiting 
Kainate, NMDA and GABAA receptors, as well as reducing glutamate excitotoxicity 
8-11. Unfortunately 
riluzole is only mildly effective, with a Cochrane library review showing a 9% improvement in the 
probability of surviving one year 12. Edaravone, is a free radical scavenger that was first developed as 
a therapeutic for ischemic stroke 13.  And Edaravone was also beneficial in the wobbler mouse model 
of ALS14 and was approved for the treatment of ALS patients in 2017 and is used in Japan, China, USA 
and UK. Edaravone could work by reducing oxidative stress in ALS patients, but the exact 
mechanisms remain unknown15. Unfortunately, edaravone only has mild effects in clinical trials, 
delaying disease progression in a subset of patients. This highlights the need for continued drug 
discovery efforts in ALS research to find next generation therapeutics to deliver benefits to patients. 
High-throughput drug discovery is a term widely used in the scientific field to describe assays that 
have been optimised to handle large numbers of samples and compounds. There are no set criteria 
for what constitutes being a HTDS, and is model and readout dependant. Computation biology has 
the capacity to screen millions of compounds, cell assays in the hundreds of thousands and in vivo 
screens in the thousands. HTDS are becoming more affordable to academia with the ability to 
generate drug discovery pipelines, utilising robotics, liquid handling, high content imaging and data 
analysis pipelines. Pharmaceutical companies are also now generating strong collaborations with 
academia to share compound libraries for neurodegenerative research. The aim of this review is to 
bring together the HTDS efforts from the field and highlight the successes and strengths of the work 
completed. Our aim is to provide an overview of the work that has been undertaken and highlight 
the gaps in the field, with suggestions on how these may be addressed, to improve future study 
design and our understanding of this neurodegenerative disorder. 
2. High-throughput Drug Screening (HTDS) in ALS 
2.1. In silico  
In silico screens and artificial intelligence (AI) technologies are an innovative and exciting way of 
screening drugs in an ultra-high throughput capacity. Using computational biology, millions of drugs 
can be tested for a predicted effect, such as binding a particular receptor or protein stabilisation, 
with the capacity to screen with many different virtual parameters, such as central nervous system 
(CNS) penetrance and ADME properties. This throughput of screening would be near impossible in a 
classical lab bench setting, without a large dedicated team, making in silico screens a very attractive 
screening platform. Also the availability of commercial and open source databases that are being 
constantly updated, further promotes in silico screening as an attractive starting point for HTDS. The 
potential limitation of these screens is that computational systems are only as smart as the database 
provided to the program and the information about the compounds being tested. In silico libraries 
are improving all the time and are fast becoming the gold standard pre-screening tool for selecting 
more focused compound libraries for taking into classical lab bench based screens. This is of 
particular importance in ALS where a large failure rate of potential therapeutics in clinical trials 
suggests better pre-screening assays are needed.   
One such in silico screen in ALS screened 1.5 million molecules for binding capacity at the SOD1 
dimer interface 16. The native state of SOD1 is as a dimer, and it was predicted that stabilising SOD1 
as a dimer may be neuroprotective in ALS. The group identified a predicted binding site for 
compounds at the dimer interface and ranked the hits on the ability to bind. The 100 compounds 
that ranked top for binding were then validated in vitro for the ability to inhibit aggregation in the 
SOD1 carrying A4V, G85R or G93A mutations. Of these top 100 compounds, 15 showed the ability to 
stabilise the SOD1 dimer and prevent mutant SOD1 aggregation. The issue with finding compounds 
that bind strongly to proteins, is the potential for strongly binding off target proteins and/or altering 
the normal protein function, leading to side effects. In biology, cellular mechanisms are constantly 
being modulated and maintained in a fine balance, which can lead to cellular disorder and disease 
when the balance is shifted. To combat this, the group refined their search criteria to test a further 
2.2 million compounds for the ability to dock specific SOD1 sites with limited off target binding 17. 
Using a library with improved ADME properties, 6 compounds were identified that served as strong 
inhibitors of mutant SOD1 misfolding, with high specificity for binding SOD1 over other plasma 
proteins. This has highlighted new compounds for further secondary testing and optimisation, as 
well as highlighting the applicability of these screens in ALS research. With advances in science and 
computing power, the key for these screens is for new data to be constantly added all the time and 
for the algorithms to evolve making these screens more powerful and informative to drive forward 
ALS drug discovery. 
SOD1 functions normally as a dimer but monomeric SOD1 have been identified in human patients 
and mouse tissues. It is hypothesised that monomeric SOD1 causes toxicity - rather than the 
aggregates and may be an early stage of disease pathology 18, 19. A computational screen of 4,400 
drugs was undertaken for binding to two sites at the SOD1 dimer interface 20. From this, 7 hits were 
taken forward for protein-protein interaction studies in A4V SOD1 mutant protein. The study 
identified antioxidant compounds that directly interact with SOD1 leading to stabilisation in the 
native state. The next stage for these drugs is further testing in cellular and animal models to show 
efficacy.  
2.2. Cell-free assays  
Misfolded proteins are a classical hallmark of ALS and protein aggregates are seen as a key indicator 
of disease pathogenesis. Aggregated, misfolded and mis-localised proteins are all seen in ALS and are 
an excellent indicator of cellular toxicity. By preventing the misfolding of proteins it is predicted that 
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other diseases argues that protein aggregates are potentially the cells way of dealing with mutant 
protein and are a way of removing mutant proteins, so the cell can continue to function 21, 22. 
However, whilst this is still very much a hot topic, it is beyond the scope of this review.  
Some HTDS in ALS have focused on modulation of protein interactions to prevent misfolding in an in 
vitro setting. These studies have the advantage of being able to investigate a single protein or 
protein-protein interaction and identify the mechanisms of protein misfolding due to a disease 
mutation, while identifying compounds that can directly modulate the protein. The ability to scale 
up these screens also means there is the capacity to test large libraries of compounds relatively 
quickly, targeting disease relevant proteins and specific mutations, while keeping costs low. The 
downside of these studies is you are investigating the interaction outside of the cell, in the absence 
of all other interactions. Another potential factor is often these studies are performed in conditions 
that push the proteins towards misfolding, such as in the presence of a denaturing agent or stressor, 
which may lead to protein conformations not seen in disease.  
Misfolding of SOD1 leads to accumulation of toxic mutant SOD1 oligomers in the spinal motor 
neurons 23. This has been suggested as a pathogenic mechanism causing toxicity in the motor 
neurons and by reducing SOD1 oligomer levels, it may be possible to reduce neuronal toxicity. One 
study used the destabilising conditions of 1M guanidine hydrochloride to induce aggregate 
formation of mutant SOD1 (G37R) protein and investigated compounds that could inhibit the 
aggregation 24. Levels of insoluble SOD1 oligomers were analysed by changes in solution turbidity 
and via non-reducing PAGE (Polyacrylamide gel electrophoresis). 640 FDA approved drugs were 
screened in this system and a group of Vitamin D derivatives and statins were identified that 
completely inhibited the formation of insoluble SOD1 oligomers. Unfortunately statins are known to 
have a strong association with functional decline in ALS patients and increased disease progression 
with reduced survival in SOD1 G93A mice 25, 26. Vitamin D however has shown some positive effects 
in mice and patients 27, 28. Although the drugs screened in this study did not directly identify a 
potential therapeutic, there is a potential to scale up the work to screen more novel compounds and 
find modulators of SOD1 oligomerisation.  
Another therapeutic target in SOD1-ALS is the interaction between mutant SOD1 protein and Derlin-
1. A previous study showed that disrupting this interaction protected MN from mutant SOD1-
induced toxicity in mouse primary spinal cord culture 29. Therefore, a cell-free HTDS assay using time 
resolved fluorescence resonance energy transfer (TR-FRET) technology was developed to identify 
compounds that disrupt mutant SOD1-Derlin-1 interaction 30. HEK293 cells were transfected with 
FLAG-tagged SOD1-G93A and HA-tagged Derlin-1, and then lysed. 160,000 compounds were then 
screened in the cell lysate, and the TR-FRET assay performed to identify compounds that disrupt the 
mutant SOD1-Derlin-1 (degradation in endoplasmic reticulum protein 1) interaction. 1,460 hit 
compounds were identified in the primary TR-FRET screen and taken forward. False positives were 
ruled out using secondary screens, and co-immunoprecipitation assays confirmed that 12 
compounds directly disrupted the mutant SOD1-Derlin-1 interaction. One potent inhibitor with good 
drug-like properties was investigated further, and prevents 122 different types of mutant SOD1 from 
interacting with Derlin-1. Additionally, the inhibitor improved iPSC-MN survival from a SOD1-ALS 
patient carrying a L114FVX mutation, and also delayed onset and improved survival in the G93A-
SOD1 mouse.  
TDP-43 protein misfolding is a major pathological hallmark of ALS and aggregates are present in 
approximately 97% of all ALS cases 6, 31, 32. TDP-43 is known to self-interact so an in vitro assay was 
designed to test 1,280 compounds for the ability to inhibit self-interaction and prevent aggregation 
33. Neuro2a cell lines were then used to confirm the compounds led to a reduction in insoluble TDP-
43 protein. A gold containing thioredoxin, Auronofin, was identified that shifted the TDP-43 protein 
from an insoluble state to a soluble state. Further investigation of this class of compounds and 
screening of larger libraries will now be critical to further understanding TDP-43 misfolding toxicity 
mechanisms.  
2.3. Cell-based assays 
Cells are powerful models for investigating human disease, and as models for use in HTDS assays. 
Cells can be cultured in large numbers and are highly amenable to genetic manipulation, allowing 
generation of robust reporter cell lines for target-based HTDS. In addition, phenotypic HTDS using 
patient-derived and disease-relevant cell types, such as MN and glial cells in ALS, is now possible due 
to the recent advances in reprogramming technologies. 
2.3.1. Reducing SOD1 transcription 
Data strongly supports that mutant SOD1 protein has a toxic gain-of-toxic function. SOD1 knockout 
causes no overt motor phenotype in mice 34, whilst mutant SOD1 over-expression causes MN loss 
and progressive paralysis in mice and rats 35, 36. Importantly, high level mutant SOD1 expression 
causes these ALS like phenotypes in the rodent models, whilst low level mutant SOD1 expression 
does not. Accordingly, reducing SOD1 protein levels was identified as one of the earliest therapeutic 
targets for SOD1-ALS. Therefore, multiple cell-based screening strategies have been employed to 
identify compounds that reduce SOD1 protein levels. Three studies screened for compounds that 
reduce SOD1 transcription 37-39, whilst others screened for compounds that inhibit SOD1 protein 
aggresome formation 40 or increase mutant SOD1 protein degradation 37. 
Reducing SOD1 transcription was the earliest strategy developed in a HTDS to reduce SOD1 protein 
levels. 116,680 compounds from 10 different libraries were screened in a stable PC12 cell line 
engineered to express an EGFP gene under the control of a 2.2 Kb fragment of the SOD1 promoter 37. 
370 hit compounds were identified in the PrSOD1-EGFP reporter line, and 29 of those reduced SOD1 
transcription and were not cytotoxic. In a separate study, the Chembridge small molecule library, 
assembled from 30,000 predicted CNS-penetrant compounds, was screened in the same PrSOD1-EGFP 
reporter cell line 39. From this library, 20 compounds reduced EGFP levels in the primary screen, 
although 17 compounds were cytotoxic at the effective doses and therefore discontinued from 
further investigation. Of the remaining 3 lead compounds, only 1 compound reduced SOD1 mRNA 
(messenger RNA) and protein levels in secondary experiments, and only slightly reduced SOD1 
protein levels in vivo in mouse spinal cord. Another group generated a stable human astrocytoma-
derived H4 cell line that expresses secreted luciferase under the control of a genomic SOD1 
promoter 38. 9,600 compounds were screened in this gPrSOD1-Luc reporter, and 115 hit compounds 
were identified and confirmed as non-cytotoxic. Using ELISA as a secondary assay, 2 of these hit 
compounds reduced SOD1 protein levels in a dose-dependent manner. However, the hit compounds 
from these three SOD1 transcriptional repressor screens are likely to be general transcriptional 
repressors, and without improving specificity toward SOD1, are not good candidate compounds for 
clinical trials. 
2.3.2. Reducing protein levels or aggregation 
Protein aggregation is a pathological hallmark of ALS. TDP-43 pathology appears in the majority of 
both sporadic and familial ALS cases 6, 7, whilst SOD1 and FUS (Fused in Sarcoma) pathologies are 
described in ALS patients with mutations in the respective genes 23, 41, 42. Reducing these 
pathogenomic protein aggregates could therefore provide an effective ALS therapy. Therefore, 
several HTDS assays have been developed to identify compounds that reduces SOD1, TDP-43 or FUS 
aggregation 37, 40, 43-45. However, it is still unknown whether the protein aggregation is toxic or 
protective in affected cells. 
To model SOD1 protein aggregation in a HTDS, COS1 cells were transduced with adenovirus 
expressing a mutant G85R-SOD1-GFP fusion protein and then treated with a proteasome inhibitor 40. 
In this system, the G85R-SOD1-GFP fusion protein formed SOD1 aggresomes. 20,000 compounds 
were screened, and 12 compounds reproducibly inhibited aggresome formation. In addition to the 
SOD1 transcriptional reporter line (described in section 2.3.1.), Broom et al. also generated a stable 
PC12 cell line with inducible G37R mutant SOD-EGFP fusion protein expression 37. The commercially 
available Prestwick and MicroSource libraries (640 and 1040 compounds respectively) were 
screened in this SOD1G37R-EGFP line to identify compounds that reduce G37R-SOD1-EGFP protein 
levels. 67 hit compounds reduced EGFP fluorescence, but the majority were either cytotoxic or failed 
to replicate in dose-response assays. Authors describe further analysis was on going for 2 of the 
compounds. 
TDP-43 and FUS are predominantly localised in the nucleus, but under cellular stress, both proteins 
can translocate to the cytoplasm and associate with stress granules 46, 47. Interestingly, ALS-causative 
mutations in TARDBP and FUS, increase the propensity for their encoded proteins to aggregate 5, 48. 
As such, aberrant stress granule dynamics could drive TDP-43 and FUS aggregation and 
proteinopathy, and could represent a key initiating event in ALS pathogenesis 49. Therefore, three 
HTDS assays were developed to screen for compounds that inhibited TDP-43 or FUS-positive stress 
granules.  
The first used a stable PC12 cell line with inducible expression of a TDP-43-GFP fusion protein, 43, 
whilst the later 2 HTDS used human-derived cells, which are covered later in section 2.3.6. Under 
basal conditions, the PC12 reporter cells had diffuse nuclear TDP-43-GFP localisation. However, TDP-
43-GFP localised to nuclear aggregates and cytoplasmic stress granules after arsenite-induced 
oxidative stress, and this phenotype was robust enough to take forward to the HTDS. A library of 
approximately 75,000 compounds was screened in this TDP-43-GFP positive stress granule assay, 
and included selected FDA-approved drugs, natural products, and commercially available 
compounds to maximise chemical diversity. 16 compounds were identified from the primary screen 
that significantly reduced TDP-43-GFP positive stress granule formation, were validated in secondary 
dose-response assays, and did not induce cellular toxicity or affect TDP-43 expression levels. Hit 
compounds were then tested in WT-TDP-43 and A315T mutant TDP-43 C.elegans lines, and one lead 
compound ameliorated TDP-43 induced MN loss and motor deficits. This is an interesting avenue of 
discovery and further work is needed to elucidate the mechanisms of stress granule formation and 
how inhibition of their formation may lead to neuroprotection. 
2.3.3. Anti-glutamatergic 
Glutamate excitotoxicity - caused by excessive glutamate in the synaptic cleft is implicated in MN 
injury and death in ALS50. One potential therapeutic approach to protect against excitotoxicity is to 
enhance synaptic glutamate reuptake by glial cells. The glial glutamate transporter (GLT-1: also 
known as EAAT2 and SLC1A2) plays a major role in glutamate clearance, and two HTDS were 
developed to identify compounds that upregulate GLT-1 expression. In the first a structurally diverse 
library of 1,040 FDA-approved drugs and nutritionals were screened in organotypic spinal cord slice 
cultures prepared from postnatal day 9 rats 51. After 5-7 days treatment, tissue was harvested for 
GLT1 protein levels, and the top hit compounds were enriched for beta-lactam antibiotics. Foetal 
astrocytes or COS7 cells transfected with a 2.7 kb GLT-1 promoter fragment linked to a reporter 
were used to confirm that the beta-lactam compounds increased GLT1 expression. A lead compound 
also increased GLT-1 protein and function in vivo, and slowed disease progression and extended 
survival in the G93A-SOD1 mouse model of ALS. 
In the second GLT-1 screen, a high throughput enzyme-linked immunosorbent assay (ELISA) was 
used to measure GLT-1 protein levels in a stable rat primary astrocyte line with high expression of 
human GLT-1 52. Approximately 140,000 small molecules were screened, including FDA-approved 
drugs, purified natural products, commercially available compounds, and small molecules procured 
from academic institutions. 293 compounds increased GLT-1 expression in the primary screen, and 
61 compounds showed a dose-response in secondary assays. 3 compounds with high potency, low 
toxicity, and chemical tractability were taken forward for lead optimisation. However, three anti-
glutamatergic compounds - memantine, talampanel, and ceftriaxone  ? all failed to show clinical 
efficacy in advanced-stage ALS clinical trials suggesting excitotoxicity modulation alone is insufficient 
for protection in ALS 53-56. 
2.3.4. Reducing oxidative stress 
Elevated levels of oxidative damage in pathologically affected areas of the CNS in ALS patients 
implicates oxidative stress in ALS pathogenesis 57. Therefore, antioxidant compounds have been 
highlighted as potential ALS therapeutics. The 2,000 compound Spectrum Collection of known drugs 
and natural products was screened for compounds with protective antioxidant properties in two 
separate HTDS 58, 59. In the first HTDS, oxidative stress was induced in NSC34 cells by serum 
withdrawal, and DCF (Dichlorofluorscein) fluorescence was used to measure reactive oxygen species 
(ROS) levels 58. 164 compounds were identified in the primary screen that significantly reduced ROS. 
These hits were further refined in subsequent assays and 2 compounds were identified that were 
neuroprotective, well tolerated in vivo, have good predicted CNS penetrance and enhanced drug-like 
properties. In the second HTDS, the Spectrum Collection was screened for compounds that 
upregulate activity of NRF2 (nuclear factor erythroid 2  ? related factor 2)  ? a transcription factor that 
binds the antioxidant response element (ARE) and drives expression of antioxidant enzymes 59. CHO 
cells were stably transfected with an ARE-EGFP construct, thereby reporting NRF2 activity. 44 NRF2 
activating compounds were identified in the primary screen, and of those, 17 were neuroprotective 
and non-cytotoxic in secondary assays, and were predicted to have good CNS penetrance. 
Encouragingly, anti-oxidant free radical scavenger edaravone has demonstrated efficacy in phase 3 
clinical trials 60, and suggests anti-oxidant compounds identified in these HTDS may also translate to 
clinic. 
2.3.5. Cytoprotection 
A key pathophysiological event in ALS is MN degeneration and loss. Therefore, several studies have 
screened to identify compounds that improve MN survival. In the first HTDS, MN from embryonic rat 
spinal cords were purified, cultured under trophic deprivation and then stained using calcein-AM to 
identify live cells 61. Approximately 40,000 compounds were screened in this phenotypic assay, and 
olesoxime was one of the most potent neuroprotective compounds. Additionally, olesoxime 
increased MN survival in a dose-dependent manner and also improved neurite outgrowth and 
axonal branching. Further, olesoxime was neuroprotective and neuroregenerative in two rodent 
models of nerve injury, and delayed onset and improved survival in G93A-SOD1 mice. However, 
olesoxime did not provide efficacy in advanced stage clinical trials of ALS 62. 
As described in section 2.3.1., mutant SOD1 likely confers toxicity through a gain-of-function 
mechanism, and therefore one HTDS was developed to identify compounds that ameliorate this 
toxicity. PC12 cells stably expressing mutant (G93A or G85R) SOD1 protein tagged with a yellow 
fluorescent protein (YFP) were used63. In the primary screening assay, PC12 G93A-SOD1-YFP cells 
were treated with the proteasome inhibitor MG132, which caused mutant SOD1 protein-induced 
cell death. Over 50,000 compounds were screened in this SOD1-toxicity assay, and compounds were 
selected to maximise chemical structural diversity and to include biologically well-characterised 
compounds (including FDA-approved and clinically tested compounds). 68 compounds improved cell 
viability, and only one false positive was identified. Secondary screening in the PC12 G85R-SOD1-YFP 
model confirmed that the vast majority of these hit compounds also inhibited SOD1-YFP 
aggregation. Chemoinformatic methodologies identified several chemical scaffolds or chemotypes 
for further testing in the aforementioned HTDS assays. As a result, 3 chemical scaffolds with good 
drug-like properties were proposed for lead optimisation to identify candidate compounds to test in 
the G93A-SOD1 mouse model, and then translate into clinical trials. 
WT murine embryonic stem cells (mESC) or mESC carrying a SOD1G93A transgene were used in 
another SOD1-toxicity HTDS 64. Both mESC lines also carry GFP under control of the MN-specific 
promoter Hb9, and were differentiated to produce Hb9-GFP+ MN for the HTDS assay. Hb9-GFP+ 
MNs were also cultured under neurotrophic factor withdrawal to induce MN death. Approximately 
5,000 compounds (including known drugs, bioactives, and chemically annotated compounds) were 
screened in both WT and G93A-SOD1 Hb9-GFP+ MNs to identify compounds that improve MN 
survival. Hit compounds from the primary screen were re-tested in a secondary dose-response 
assay. The GSK-3 inhibitor kenpaullone was the most protective compound tested in both WT and 
mutant MN, and was taken forward for further analysis. The compound also reduced mutant SOD1 
protein levels in G93A-SOD1 MN, and improved MN survival in cultures derived from iPSC from 
TARDBP-ALS, SOD1-ALS as well as from a heathy control. Critically, this HTDS identified the HGK-
Tak1-MKK4-JNK-c-Jun cell death signalling cascade as a potential therapeutic target in ALS. 
2.3.6. Patient/Human-derived cell models 
For a long time, scarcity of human cells from the CNS has posed a serious challenge to studying 
and understanding complex neurodegenerative disorders such as ALS. However, over the last 12 
years, ground-breaking human cell reprogramming technologies have advanced rapidly. Human 
somatic cells can now be reprogrammed to induced pluripotent stem cells (iPSC) 65, 66, which can 
then be differentiated into neuronal progenitor cells (NPC), and subsequently into neuronal and 
glial cells 67. More recently, transdifferentiation methologies allow the generation of NPCs 
directly from fibroblasts 68-70. As such, reprogramming technologies present drug discovery 
scientists with a readily available source of ALS patient derived neurons and glial cells that retain 
key pathophysiological properties of ALS, and can be utilised for pathophysiologically relevant 
phenotypic drug screening. 
Burkhardt et al., were the first group to use ALS patient derived cells in a phenotypic HTDS assay 45. 
In the study, fibroblasts from 10 healthy controls, 8 familial ALS patients, and 16 sporadic ALS 
patients were reprogrammed into iPSC. All iPSC lines were then differentiated into MN (iPSC-MN), 
and characterised for TDP-43 proteinopathy. In iPSC-MN from 3 of the sporadic ALS patient lines, 
neurons contained spontaneous intranuclear TDP-43 aggregates that were hyper-phosphorylated 
and morphologically similar to TDP-43 aggregates seen in ALS patient post-mortem CNS 6, 31, 71. 
Although intranuclear TDP-43 aggregates are less commonly described in ALS post-mortem tissue, 
one of the sporadic ALS patients displays the intranuclear TDP-43 aggregates both in vitro in the 
iPSC-MN and post-mortem in spinal cord and frontal lobe neurons. Using one of the sporadic ALS 
patient iPSC-MNs that display nuclear TDP-43 inclusions, a HTDS was developed to identify 
compounds that could reduce TDP-43 aggregation. 1,757 compounds were screened, and 38 hit 
compounds reduced the percentage of iPSC-MN cells that contained TDP-43 aggregates. The hits 
were tested on cortical neurons derived from the same ALS patient iPSC in a secondary dose-
response assay, and 4 classes of compounds were identified that reduced TDP-43 aggregates in a 
dose-dependent manner. 
In another HTDS, CRISPR-Cas9n (clustered regularly interspaced short palindromic repeats) gene 
editing technology was used to generate iPSC reporter cell lines with an ALS causative FUS mutation 
44. The iPSC were derived from a healthy donor control, and eGFP was inserted into the C-terminal 
domain of genomic FUS. Additionally, isogenic iPSC lines were generated with or without the ALS-
causative P525L mutation in genomic FUS. The P525L mutation lies in the nuclear localisation signal 
(NLS) of FUS, and increased cytoplasmic FUS mislocalisation in the iPSC. The P525L mutation also 
increased FUS-eGFP recruitment to stress granules after sodium arsenite treatment, and formed the 
basis of the HTDS assay. Approximately 1,000 compounds against known targets were screened in 
the P525L-FUS-eGFP iPSC to identify compounds and molecular pathways that affect stress granule 
dynamics. 96 hit compounds reduced FUS-eGFP+ stress granule area in the primary screen, and 13 
hits inhibited the PI3K/AKT/mTOR (mammalian target of rapamycin) signalling pathway  ? which 
inhibits autophagy and was assessed in secondary experiments. In neuronal cultures derived from 
the P525L-FUS-eGFP iPSC lines, autophagy stimulation using mTOR inhibitors ameliorated stress 
granule dysfunction, reduced neuronal apoptosis, and improved axonal branching and health. 
Further, genetic upregulation of autophagy extended lifespan and ameliorated retinal 
neurodegeneration in transgenic drosophila models expressing WT or mutant FUS in the CNS or 
retina respectively. This study corroborates a link between autophagy and stress granule dynamics, 
and highlights autophagy stimulation as a potential therapeutic target in ALS. Finally, a second HTDS 
was performed in the P525L-FUS-eGFP iPSC stress granule assay using approximately 1,600 US Drug 
Collection MicroSource Discovery compounds to identify clinically approved drugs that could reduce 
the FUS-ALS stress granule phenotype. Incredibly, 70 hit compounds were identified, that included a 
number of brain-penetrant anti-psychotics and anti-depressants that are known autophagy inducers. 
Importantly, 2 of these clinically approved compounds are brain-penetrant and share a chemical 
scaffold that could be taken forward for lead optimisation. 
 
The third HTDS using patient-derived cells assayed for iPSC-MN survival 69. iPSC-MN derived from 
ALS patients had worse survival than iPSC-MN derived from healthy donor controls, and this 
pathophysiologically-relevant phenotype was developed into a HTDS assay. 1,416 compounds, 
including clinically approved drugs and compounds undergoing clinical testing, were screened in 
iPSC-MN from a SOD1-ALS patient carrying a L114FVX mutation. 27 hit compounds improved MN 
survival in the primary screen, and 14 of these compounds target the Src/c-Abl signalling pathway. 
Genetic knockdown of Src and c-Abl using siRNA also improved SOD1-ALS iPSC-MN survival, 
warranting further investigation into this pathway. Several Src/c-Abl inhibitors were also validated in 
dose-response MN survival assays, and bosutinib  ? which had the lowest EC50 - was taken forward 
for further analysis. Bosutinib also improved iPSC-MN survival in cells derived from 8 familial ALS 
patients (containing mutations in SOD1, C9ORF72, or TARDBP) and also in 2 of 3 sporadic ALS 
patients. Finally, bosutinib also delayed onset, improved survival, increased spinal MN counts, and 
reduced misfolded SOD1 in the G93A-SOD1 mouse.  
The final HTDS using patient-derived cells also assayed for improved iPSC-MN survival, in addition to 
other relevant phenotypes73. iPSC-DEĚĞƌŝǀĞĚĨƌŽŵ>^ƉĂƚŝĞŶƚƐĚŝƐƉůĂǇĞĚ ‘>^ƉŚĞŶŽƚǇƉĞƐ ?
including reduced neurite length, increased caspase 3 cleavage, increased LDH leakage, increased 
number of stress granules, and had FUS or TDP-43 aggregates  ? dependent on genetic subtype  ? 
compared to iPSC-MN derived from healthy controls. 1,232 approved drugs were initially screened in 
FUS-ALS iPSC-MN cultures in which four of these ALS phenotypes were measured. 95 compounds 
rescued the four pathophysiologically relevant phenotypes measured, and the compounds were re-
tested in a similar multi-phenotypic dose-response assay using TARDBP-ALS iPSC-MN. Consequently, 
nine compounds were identified that improved the ALS phenotypes, and ropinirole  ? a dopamine D2 
receptor agonist - was selected as the lead candidate based on brain-penetrance, side effects, and 
dose-response. Additionally, ropinirole corrected these ALS phenotypes in 16 out of 22 iPSC-MN 
derived from different sporadic ALS patients. Identification of genomic or transcriptomic signatures  ? 
or other clinical phenotypes or biomarkers - that could differentiate the ropinirole responders from 
non-responders could allow patient stratification in potential ropinirole clinical trials  ? setting a 
precedent in ALS clinical trials and drug discovery. 
 
2.4 In vivo   
In vivo screens are one of the most challenging models to develop and optimise for HTDS. Comparing 
different animal models of ALS is beyond the scope of this review, but is expertly covered in 74. In 
vivo models allow the generation of multiple data sets such as behaviour, survival and the collection 
of different tissue types meaning large cohorts of data can be generated from each study. The 
negative side is that model generation and validation HTDS can be difficult and time consuming, 
making in vivo HTDS increasingly difficult. Often large numbers of animals are required for each 
compound as well as large quantities of drugs and lengthy exposures, making study design and cost 
effectiveness difficult. To combat this, large screening studies have moved away from the classical 
murine models to use novel animal models such as drosophila, c.elegans and zebrafish to perform 
HTDS. These models maintain the cellular complexity of larger mammalian models but have the 
advantages of being cheaper, developing faster and being more amenable to developing large scale 
screening studies. The downside is that these models are often evolutionarily and genetically further 
away from mammalian models, but act as excellent in vivo systems for pre-screening large numbers 
of compounds, before testing in mammalian models.  
C.elegans are nematode worms with a simple nervous system, consisting of 302 neurons and 50 glial 
cells, alongside a fully sequenced genome. Their small size, conserved genetics and rapid 
development make them an excellent model for developing HTDS assays. C.elegans carrying a 
TARDBP mutant were used to screen 3,850 compounds in a phenotypic screen for improving motor 
behaviour 75. C.elegans were pooled and treated with compounds for 6 hours before the group 
looked for a rescue effect on motor behaviour. From the 13 positive hits identified, the group then 
screened in zebrafish models expressing mutant TDP-43, SOD1 or FUS to confirm that compounds 
improved motor behaviour. Ten hits were identified in the zebrafish screen, which included a family 
of neuroleptic compounds. The most potent hit, pimozide, a T-type Ca2+ blocker, was then tested in 
the SOD1 G93A mouse and in a small scale human clinical trial where treatment with pimozide 
confirmed stabilisation of motility in patients. This work is an excellent example of how screening in 
invertebrates and lower organisms can be a powerful pre-screening tool for therapeutic effect 
before confirming the positive effect of compounds in mammalian models.  
Another commonly used laboratory in vivo model is the drosophila. Drosophila are a small fruit fly 
with a well-defined developmental pathway, rapid development, conserved genetics and fully 
sequenced genome, allowing the generation of specific mutant models of neurological disorders. 
Mutant TDP-43 causes pupal larval lethality in drosophila, and a therefore, 1,200 compounds were 
screened in a mutant TDP-43 drosophila model to identify compounds that could ameliorate this 
phenotype 76. The PPAR (peroxisome proliferator activated receptors) agonist, pioglitazone, was 
identified as neuroprotective, rescuing locomotor defects and extending larval survival in the 
drosophila. It was also shown that pioglitazone does not extend survival in adult mTDP-43 or mFUS 
drosophila, but has neuroprotective effects, highlighting WWZ ?ƐĂƐĂƉŽƚĞŶƚŝĂůƚŚĞƌĂƉĞƵƚŝĐƚĂƌŐĞƚĨŽƌ
further investigation. Pioglitazone was shown to protect against toxicity in a tissue specific manner, 
with protection of glial cells, but not muscle. Interestingly the drug had no effect on SOD1 mutants 
highlighting the ability for these models to identify therapeutic agents with mutation specific effects. 
This highlights the power of in vivo studies to give large amounts of information, identifying that a 
drug is having a neuroprotective effect but that it was cell specific. 
Zebrafish are another widely used in vivo model due to their rapid development, conserved genetics 
and applicability to HTDS. A high-throughput screening method has been developed using zebrafish 
embryos to screen for potential ALS therapeutics. A mutant sod1 G93R zebrafish model was utilised 
to screen 2,000 compounds for their ability to reduce mutant SOD1 toxicity 77. The sod1 zebrafish 
model contains an hsp70-DsRed construct which allows the visualisation of cellular stress as an 
increase in DsRed fluorescence. Drug effect was measured by looking for compounds that showed 
reduced DsRed, indicative of a reduction in neuronal stress. This screen has the capacity to screen 
over 500 compounds per week with over 90% specificity and sensitivity. 7 compounds were found to 
strongly reduce neuronal stress and a lead compound which is neuroprotective in the zebrafish, is 
now being tested in the SOD1 mouse mode (unpublished data). In vivo drug screens have the 
potential to be very powerful and deliver large amounts of data. Study design and assay optimisation 
is a critical step when designing in vivo screens and choosing the correct model to answer your 
research hypothesis is imperative.  
Conclusions: 
ALS is a rapidly progressive neurodegenerative disease caused by a wide range of complex genetic 
and environmental factors. Riluzole and edaravone are currently the only two clinically approved 
compounds for ALS treatment - both of which only have a modest effect on disease progression and 
survival. Therefore, there is a desperate need to identify new efficacious compounds, and a variety 
of high-throughput drug screens have been developed and undertaken in the ALS field to achieve 
this. These screens have used a wide range of different model systems, modelling various genetic 
subtypes of ALS, as well as aiming for a wide range of different molecular targets and/or phenotypic 
outcomes. A summary of all the trials is available in table 1. This highlights the complexity of ALS but 
also the huge amount of drug discovery research that has already been undertaken for ALS 
therapeutics. 
Expert Opinions 
 
HTDS are powerful starting points in drug discovery to identify novel compounds and chemical 
structures as therapeutic candidates. However, the vast majority of clinical trials investigating 
potential ALS therapeutics have failed to show clinical efficacy74, and these failures include candidate 
compounds identified from HTDS. Therefore, we need to reassess how best to implement HTDS in 
the ALS drug discovery process. We believe advancements in disease understanding, computational 
disease modelling, animal and patient derived cell models, as well as increased application of 
artificial intelligence and patient stratification, will improve the identification and translation of lead 
compounds from HTDS into clinical efficacy.Phenotypic, genetic, and pathophysiologic heterogeneity 
make ALS an incredibly complex disease.  
Mutations in over 30 genes are known to cause ALS, and these different mutations are likely to drive 
different pathogenic pathways that culminate in MN degeneration and manifest as an ALS 
phenotype. The heterogeneity of the disease has likely contributed to the poor success of clinical 
trials, and currently there is no single well defined therapeutic target for the total ALS population. 
Therefore, we predict phenotypic screening - which does not require a pre-defined molecular 
mechanism of action (MMOA)  ? will be more productive than target-based screening in identifying 
efficacious lead compounds for ALS as a whole population. As such, the advance of patient-derived 
in vitro cell models that recapitulate pathophysiological aspects of ALS will be key models for HTDS. 
In addition, generation and development of better animal models of ALS - particularly mouse models 
where therapeutic identification has had a high failure rate in clinical trials - are needed. These 
patient-derived in vitro and new in vivo models are the future gold standard models for HTDS in ALS.  
Additionally, given the heterogeneity, certain therapeutics may only work on specific genetic or 
pathophysiologic subtypes of ALS, and multiple different precision medicine strategies may be 
necessary to treat the whole ALS population. To demonstrate this, post-hoc meta-analysis was 
performed on data from multiple ALS clinical trials of lithium carbonate 79. Lithium carbonate was 
not efficacious in the total ALS population; however, lithium carbonate did improve survival in a 
genetic subtype of patients carrying UNC13A mutations. In addition, SOD1 antisense oligonucleotide 
therapy80, arimoclomol81 and pyrimethamine82 may provide efficacy specifically in ALS patients with 
SOD1 mutations. In future, better patient stratification should help assign efficacious therapeutics to 
the correct patients and ALS subtypes. These breakthroughs are most likely to come from improved 
genetic screening and biomarker development, which will allow for more specific personalised 
medicine approaches. This will hopefully lead to improved therapeutic effects and improved success 
rates in stratified clinical trials.  
Also, ALS therapeutics will only provide efficacy if they reach the CNS by crossing the blood-CNS 
barrier (B-CNS-B). Multiple studies implicate B-CNS-B impairment in ALS patients, which likely 
impedes drug delivery into the CNS 83. For example, perivascular collagen IV accumulation seen in 
SALS patients - but not in SOD1 mouse models of ALS  ? may attribute to poor drug delivery to the 
CNS 84. Therefore, animal models that more accurately model the B-CNS-B of ALS pathophysiology 
will give a more accurate prediction of CNS penetrance of potential ALS compounds. 
Lastly, artificial intelligence has the potential to improve the efficiency of drug discovery at many 
stages of the pipeline. Scientists cannot accurately assimilate, process or recall the sheer amount of 
scientific data ŝŶƚŚĞŝƌŽǁŶĚŝƐĞĂƐĞ ?ƐĨŝĞůĚ ?ůĞƚĂůŽŶĞƚŚĞǁŚŽůĞƐĐŝĞŶƚŝĨŝĐƌĞƐĞĂƌĐŚĨŝĞůĚ ? that has been 
generated over the last few decades. However, AI technology is being developed to digest and 
interpret ƚŚŝƐŝŶĨŽƌŵĂƚŝŽŶ ?ĂŶĚŵĂŬĞ ‘ŚŝĚĚĞŶŬŶŽǁůĞĚŐĞ ?ƵƐĂďůĞƚŽƌĞƐĞĂƌĐŚĞƌƐ ?ƐĂƌĞƐƵůƚ ?/ǁŝůů
improve target selection for HTDS and aid lead compound optimisation. Additionally, with greater 
genetic characterisation of ALS patients recruited to clinical trials, AI may help identify responsive 
genetic subtypes of patients from clinical trials. 
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 Model 
number of compounds 
in primary screen Lead hits 
reference and 
year 
Ref 
No  
Computational 1,500,000 15 hits - available in orginal paper Ray et al, 2005 16 
Computational 2,200,000 6 hits - available in original paper Nowak et al, 2010 17 
Computational 4,400 
quercertin, quercetin 3-beta-d-glucoside, and epigallocatechin gallate 
(EGCG) Ip et al, 2017 20 
Protein interaction 640 Vitamin D derivatives and statins Anzai et al, 2016 24 
Protein interaction 160,000 Unknown 
Tsuburaya et al, 
2018 30 
Protein interaction 1,280 auronofin, chelerythine and riluzole 
Oberstadt et al, 
2018 33 
PC12 cell line 116,680 Unknown Broom et al, 2006 37 
Astrocytoma derived H4 cell 
line 9,600 2 hits - structure available 
Murakami et al, 
2011 38 
PC12 cell line 30,000 
N-{4-[4-(4-methylbenzoyl)-1-piperazinyl]phenyl}-2-
thiophenecarboxamide Wright et al, 2012 39 
COS1 cell line 20,000 
Cardiac glycosides, scriptaid, and DPD ((5-(3-Dimethylamino-
propylamino)-3,10-dimethyl-10H-pyrimidol[4,5-b]quinolone-2,4-dione) 
Corcoran et al, 
2004 40 
PC12 cell line 75,000 One unnamed compound Boyd et al, 2014 43 
iPSC 1,000 96 hits including 13 PI3K/AKT/mTOR pathway inhibitors 
Marrone et al, 
2018 44 
iPSC 1,600 paroxetine, promethazine, and trimipramine 
Marrone et al, 
2018 44 
iPSC-derived motor neurons 1,757 38 hits - including 4 different classes of compounds 
Burkhardt et al, 
2013 45 
rat spinal cord slice cultures 1,040 beta-lactam compounds 
Rothstein et al, 
2005 51 
rat primary astrocyte line 140,000 293 hits - 3 selected for lead optimisation Colton et al, 2010 52 
NSC34 cell line 2,000 CAPE and esculetin Barber et al, 2009 59 
CHO cell line 2,000 andrographolide and s[+]apomorphine Mead et al, 2013 59 
embryonic rat spinal cord 
derived motor neurons 40,000 olesoxime Bordet et al, 2007 61 
TDP-43 Phenotypic screen 50,000 
arylsulfanyl pyrazolones, cyclohexane-1,3-dione, and pyrimidine 2,4,6-
trione 
Benmohamed et 
al, 2011 63 
murine embryonic stem cell 
derived motor neurons 5,000 kenpaullone Yang et al, 2013 64 
iPSC-derived motor neurons 1,416 bosutinib 
Imamura et al, 
2017 83 
iPSC-derived motor neurons 1,232 ropinirole 
Fujimori et al, 
2018 73 
C.elegans 3,850 neuroleptics - pimozide Patten et al, 2017 75 
Drosophilla 1,200 piolglitazone Joardar et al, 2015 76 
Zebrafish 2,000 Unknown 
mcgown et al, 
2016 77 
 
